Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of recombinant human
tumor necrosis factor-α (rhTNF-α) when given as a single dose intravenously and in
combination with liposomal doxorubicin in human subjects